Emmaus Life Sciences Announces Willis C. Lee as Chief Executive OfficerJuly 23, 2024
Emmaus Life Sciences, Inc., announced that Willis C. Lee has been appointed as Chief Executive Officer.
Read MoreEmmaus Life Sciences, Inc., announced that Willis C. Lee has been appointed as Chief Executive Officer.
Read MoreEmmaus Life Sciences, Inc., today announced receiving the coveted "No Action Indicated" classification following a routine inspection by the United States Food and Drug Administration (FDA) of Emmaus' Postmarketing Adverse Drug Experience (PADE) compliance program.
Read MoreEmmaus Life Sciences, Inc., today reported on its financial condition and results of operations as of and for the year ended December 31, 2023.
Read MoreEmmaus reported today that the filing of its Annual Report on Form 10-K for the year ended December 31, 2023 will be delayed.
Read MoreEmmaus Life Sciences, Inc. today announced that it has received marketing authorization from the Puerto Rico Department of Health for Endari® (L-glutamine oral powder).
Read More